Loading…
JulyMD sold unapproved and misbranded compounded semaglutide drugs over the internet by making false or misleading claims that their products were equivalent to FDA-approved Ozempic and Wegovy while offering them at lower prices. The company violated the Federal Food, Drug, and Cosmetic Act by advertising compounded drugs—which are not FDA-approved—as having "the same active ingredient" and being "the same effective ingredient" as approved products, thereby misrepresenting the safety and efficacy status of their offerings. These marketing claims on JulyMD's website constituted prohibited misbranding under sections 502(a) and 502(bb) of the FDCA and violated the prohibition on introducing misbranded drugs into interstate commerce.